Thus, these gene fusions, specifically TMPRSS2-ERG fusions, could be used as targets for effective prevention/intervention strategies and stratification of homogenous PCa patient populations in drug efficacy trials [36,37]. The gene discussed is ERG; the disease is posterior cortical atrophy.